Comprehensive analysis of cardiovascular benefits of GLP-1 receptor agonists. Covers SELECT, LEADER, SUSTAIN-6, and REWIND trials showing reduced heart attacks, strokes, and cardiovascular death.
Keywords Diabetes, GLP-1 receptor agonists, Cardiovascular events, Real-world.GLP-1 receptor agonists (GLP-1 RAs) have been employed for over a decade for the treatment of type 2 diabetes mellitus.
In contrast, GLP-1-R agonists effectively reduce stroke events in patients with T2DM and established ASCVD, and thus have been implemented into recommendations for the stroke prevention of several associations, such as the American Stroke Association [9].
The article discusses the advancement of orally available small-molecule GLP-1 receptor agonists (GLP-1RAs) in diabetes management, improving glycemic control, weight loss, and patient adherence while addressing cardiovascular and renal comorbidities.
Recent literature shows that GLP-1 receptor agonists are highly effective for weight loss and improving metabolic and cardiovascular health, often surpassing...
As we can see from the illustration, Glp-1 Receptor Agonist And Cardiovascular Events has many fascinating aspects to explore.
Use of GLP-1 receptor agonists in special populations. Pharmacokinetic properties may depend on renal and hepatic function, depending on the routes of elimination.
Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol.Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in type 2 diabetes mellitus: is it a class effect?.
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
